1 ASX dividend stock down 49% I'd buy right now

I think this business is now very appealing.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ASX dividend stock Regis Healthcare Ltd (ASX: REG) has fallen a huge 49% from its high just over a year ago and this looks like a great time to invest.

Regis is one of the largest aged care operators in Australia. It provides services to more than 10,000 older Australians through residential aged care homes, home care service hubs, day therapy, respite centres and retirement villages.

Some of the decline happened earlier this month after the company noted that the Australian National Aged Care Classification (AN-ACC) starting price will increase 2.55% from $295.64 to $303.19, starting 1 October 2026.

The government also announced that the hotelling supplement will remain unchanged at $22.15 per resident per day.

Regis Healthcare said that the price increase is significantly below cost inflation in the sector and the broader economy.

I think the ASX dividend stock is a buy for multiple reasons.

A elder man and woman lean over their balcony with a cuppa, indicating share rpice movement for ASX retirement shares

Image source: Getty Images

Significantly cheaper

It's clear that conditions in the short-term are more challenging for Regis Healthcare, but I think the share price has more than made up for that.

It has fallen by roughly half in the space of a year. A share price is meant to reflect a company's long-term future potential. I don't think its long-term prospects have worsened by around 50%.

The company is still benefiting from the long-term tailwind of Australia's ageing population. In FY26, its total occupied bed days increased 8.4% to 2.85 million, with its average occupancy increased by 0.7 percentage points to 95.8%.

FY26's aged care revenue per occupied bed grew 6.7%, while aged care staff expenses per occupied bed rose 8.3%.

FY26 underlying operating profit (EBITDA) climbed 10% to $138 million, underlying net profit grew 4% to $55.6 million, and statutory net profit rose 14% to $55.7 million.

After falling so far, the business now trades at a much more appealing price/earnings (P/E) ratio.

According to the forecast on Commsec, the Regis Healthcare share price is now valued at 28x FY27's estimated earnings.

Regis Healthcare said the industry requires 10,000 new beds per year to meet potential demand. In 2025, the industry added around 800 beds, falling well short of that target. As one of the big players in the sector, the ASX share will be an important player in meeting that demand in the coming years.

Mitigating actions to help protect against margin reduction

While the latest price update for aged care providers may not match expense growth, it will partially offset the rise in costs. Plus, the ASX dividend stock is undertaking a range of initiatives to mitigate ongoing margin pressures.

Its initiatives include an increase to room prices, a rollout of 'higher everyday living fee (HELF)' services, other revenue optimisation, and operational efficiency initiatives.

Hopefully those ideas will help reduce the burden of increased costs, without reducing service at its homes.

Pleasing dividend credentials with the ASX dividend stock

I'm not expecting a dividend increase from the business every year, though it has increased its annual payout each year for the last four consecutive years.

FY27 could see a reduction based on likely reduced profitability, but then projections suggest a return to regular dividend growth in the subsequent years.

According to the projection on Commsec, it could pay an annual dividend per share of 15.1 cents in FY27. That'd be a grossed-up dividend yield of 4.6%, including franking credits.

The FY29 annual dividend is projected to be 19.2 cents per share – larger than the FY26 dividend. This would be a grossed-up dividend yield of 5.8%, including franking credits.

I believe the ASX dividend stock's payout could grow materially over the next five to ten years as ageing-demographic tailwinds continue to strengthen. This could be a good time to pounce.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man in a business suit jumps over a hurdle with a blue sky background.
Healthcare Shares

Why brokers think CSL shares could be on track for $200

CSL needs to tick a lot of boxes, before it can clear the $200 hurdle.

Read more »

Two scientists looking at a tablet.
Healthcare Shares

Telix Pharmaceuticals: ITM merger builds a sector leader

Telix Pharmaceuticals share price is in focus after announcing a transformative merger with ITM, set to expand its radiopharmaceutical pipeline.

Read more »

Six smiling health workers pose for a selfie.
ASX Share Market News

ASX 200 healthcare shares lead a weaker market amid 82% chance of a rate hike

Healthcare shares gained 3.76% while the ASX 200 fell 0.11% last week.

Read more »

Doctor analysing x-rays.
Healthcare Shares

4DMedical shares are rocketing 11% today. Is a short squeeze starting?

Short sellers may be feeling the heat after this week’s rally.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Shares surge as ASX biotech charts road to redemption

A recent major setback might not be so bad.

Read more »

Young doctor raising arms in air with hands in fists celebrating a new development.
Healthcare Shares

Forget CSL shares, I'd buy this ASX biotech stock instead

Brokers tip this other ASX biotech stock to climb up to 76% higher.

Read more »

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused.
Healthcare Shares

CSL acknowledges "disappointing" results but aims to do better

The search for a new CEO also goes on.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Healthcare Shares

CSL, Resmed, and more. See which ASX health stocks RBC Capital Markets has upgraded

This sector is coming back into favour.

Read more »